

CURRICULUM VITAE

Timothy L. Zisman, M.D., M.P.H.
Virginia Mason Medical Center

Professional Address:

Virginia Mason Medical Center
Digestive Disease Institute
1100 Ninth Ave, C3-GAS, Seattle, WA 98101
Phone: (206) 223-2319 Clinic
Fax: (206) 341-1405

1. Education:

1997 B.S., University of Michigan, Ann Arbor, MI
2003 M.D., Virginia Commonwealth University, Richmond, VA
2003 M.P.H., Harvard University, Boston, MA

2. Postgraduate Training:

2003-2006 Resident, Department of Internal Medicine, University of Chicago Medical Center, Chicago, IL
2006-2009 Fellow, Department of Medicine, Division of Gastroenterology, University of Chicago Medical Center, Chicago, IL

4. Faculty Positions Held:

2009-2015 Assistant Professor of Medicine, University of Washington
2015-2019 Associate Professor of Medicine, University of Washington
2019-present Clinical Associate Professor of Medicine, University of Washington

5. Hospital Positions Held:

2009-present Attending physician, University of Washington Medical Center
2009-present Attending physician, Harborview Hospital
2009-present Attending physician, VA Puget Sound
2019-present Attending physician, Virginia Mason Medical Center

6. Current employment:

Attending physician, Virginia Mason Medical Center

8. Honors

2003 Certificate of Recognition for Outstanding Teaching to Medical Students
2007 AGA Trainee Scholarship in Inflammatory Bowel Disease
2011 Teamwork, Leadership and Caring Award—UW Medical Center

8. Board Certification:

2006-2016 Internal Medicine, American Board of Internal Medicine

2009-current Gastroenterology, American Board of Internal Medicine
2011-2020 ACLS/BLS certification

9. Current License to Practice:

2009-present Washington

10. Professional Organizations:

- 2009-present American Gastroenterological Association, Member
- 2009-present American College of Gastroenterology, Member
- 2009-present American Society for Gastrointestinal Endoscopy, Member
- 2009-present Crohn's and Colitis Foundation, Member Chapter Medical Advisory Committee

11. Teaching Responsibilities:

Housestaff teaching:

Lectures to housestaff:

- Jul 2010 "Management of Acute Severe Colitis", *Frontiers in Gastroenterology*
- Aug 2010 "Ulcerative Colitis", *Internal medicine residents noon conference, VAMC*
- Oct 2010 Evidence-based Medicine, *GI Fellows Seminar*
- Nov 2010 "C. difficile and IBD", *Frontiers in Gastroenterology*
- Jan 2011 "Inflammatory Bowel Disease", *Internal medicine residents noon conference, UWMC*
- Jul 2011 "IBD Emergencies", *Frontiers in Gastroenterology*
- Jun 2012 "Large Bowel Disorders", *Internal medicine residents noon conference, UWMC*
- Jun 2012 "Inflammatory Bowel Disease", *Internal medicine residents noon conference, UWMC*
- Jul 2013 "IBD Emergencies", *Frontiers in Gastroenterology*
- Jul 2014 "Management of severe UC and IBD Emergencies", *Frontiers in Gastroenterology*
- Jul 2015 "Acute colitis and IBD Emergencies", *Frontiers in Gastroenterology*
- Jun 2016 "Celiac Disease", *Internal medicine residents noon conference, UWMC*
- Jul 2016 "Management of IBD Emergencies and Severe UC", *Frontiers in Gastroenterology*
- Sep 2016 "Large Bowel Disorders", *Internal medicine residents noon conference, UWMC*
- Jul 2017 "Acute colitis and IBD Emergencies", *Frontiers in Gastroenterology*

Recent CME presentations:

- Jun 2010 "Best of Inflammatory Bowel Disease", *Best of DDW Conference, Seattle, WA.*
- Apr 2011 "Updates on GI Drugs", *Current Concepts in Drug Therapy, Seattle, WA*
- Jun 2012 "Best of DDW in IBD-2012", *Best of DDW conference, Seattle, WA.*
- Sep 2012 "Diarrhea and IBS", *What's New in Medicine Conference, Kennewick, WA.*
- Sep 2012 "Updates in Gastroenterology" *Advances in Family Practice and Primary Care, Seattle, WA.*
- Mar 2013 "Cancer and Dysplasia in IBD", *Virginia Mason Updates in Inflammatory Bowel Disease Symposium, Seattle WA*
- Mar 2013 "Updates on Inflammatory Bowel Disease Therapies", *Current Concepts in Drug Therapy, Seattle, WA*
- Jun 2013 "Cancer in IBD and Future Therapies", *Wound Ostomy and Continence Nurses Society national conference. Seattle, WA.*
- Feb 2014 "Recapturing Response to Biologics and Immunomodulators in IBD" UC Irvine 6th Annual Gastroenterology and Hepatology Symposium. Anaheim, CA.
- Mar 2014 "Fecal Microbiota Transplantation for IBD", *Virginia Mason Updates in IBD Symposium, Seattle, WA*
- Mar 2014 "Updates in Inflammatory Bowel Disease", *UW Medical Center Grand Rounds, Seattle, WA.*

- May 2014 "Postoperative Medical Management of Crohn's Disease: Prevention and Surveillance Strategies", *American Society of Colon and Rectal Surgeons national conference*. Hollywood, FL.
- Sep 2014 "Case Studies in Gastroenterology", *Advances in Family Practice and Primary Care*, Seattle, WA.
- Nov 2014 "Extraintestinal Manifestations of IBD", *Best Practices in IBD Management*. Renton, WA
- Dec 2014 "Positioning Vedolizumab in the IBD Treatment Algorithm", *Frontiers in Gastroenterology*, Seattle, WA
- Mar 2015 "Optimizing Therapy for IBD", *UW Eastside Specialty Center Grand Rounds*, Bellevue, WA.
- Mar 2015 "Vedolizumab Should Be Used as a First Line Biologic in IBD", *Virginia Mason Updates in IBD Symposium*, Seattle, WA
- Jul 2015 "Inflammatory Bowel Disease", *Institute of Women's Health Conference*, Portland, OR.
- Mar 2016 "Chromoendoscopy Should be Used for Surveillance in IBD", *Virginia Mason Updates in IBD Symposium*, Seattle, WA
- Mar 2017 "Ustekinumab Should be Used as First Line Therapy for Crohn's Disease", *Virginia Mason Updates in IBD Symposium*, Seattle, WA
- Oct 2017 "Updates in Inflammatory Bowel Disease", *Pacific Northwest Society for GI Nurses and Associates Annual Conference*, Lynwood, WA
- Oct 2017 "Fecal Microbiota Transplantation for Inflammatory Bowel Disease, *Crohn's and Colitis Foundation meeting*, Las Vegas, NV
- Mar 2018 "Is Dietary Treatment Effective for IBD?", *Virginia Mason Updates in IBD Symposium*, Seattle, WA
- Mar 2019 "Tofacitinib Should Be Used as First line Therapy for Ulcerative Colitis", *Virginia Mason Updates in IBD Symposium*, Seattle, WA

Other Presentations:

- Mar 2004 "An Idiopathic, Refractory Non-Productive Cough in a Crohn's Patient and its Response to Infliximab: A Case Report". *Department of Medicine Housestaff Scientific Session*, University of Chicago. Chicago, IL
- Dec 2006 "C. difficile and IBD: What's the Connection?" *GI Grand Rounds*, University of Chicago. Chicago, IL
- Nov 2007 "Risk Factors and Outcomes Associated with *C. difficile* Infection in Hospitalized Patients with Inflammatory Bowel Disease". *Methodologies in Healthcare Outcomes in Gastroenterology: A Workshop Symposium*. Hollywood, FL.
- July 2008 "Infections in IBD". *IBD Immersion Program*. Chicago, IL.
- Sep 2009 "IBD Therapies: What Every Patient Needs to Know". *Eastern Washington IBD Connections educational symposium*, Richland, WA.
- Mar 2010 "Nontraditional Theories about Causes and Treatments of IBD", *Western Washington IBD Connections educational symposium*, Seattle, WA
- Apr 2010 "Inflammatory Bowel Disease: Past, Present and Future", *CCFA Northwest Chapter annual luncheon*, Seattle, WA.
- Nov 2010 "IBD 101 for Nurses and Medical Assistants", *Best Practices in IBD Management Conference*, Renton, WA.
- Mar 2011 "IBD Therapies and Side Effects", *Western Washington IBD Connections educational symposium*, Seattle, WA

- Nov 2011 "IBD 101 for Nurses and Medical Assistants", *Best Practices in IBD Management Conference*, Renton, WA.
- Apr 2012 "Empowering the IBD Patient: Minimizing Risk and Maintaining Good Health in IBD", *Western Washington IBD Connections educational symposium*, Seattle, WA
- Apr 2016 "Alternative Therapies for IBD", *Western Washington IBD Connections educational symposium*, Seattle, WA

12. Editorial Responsibilities:

None

13. Special National Responsibilities:

- 2009-2012 Crohn's and Colitis Foundation of America, National Education and Support Committee
- 2017-2019 American Gastroenterological Association Community Forum Moderator

14. Special Local Responsibilities:

- 2009-2015 Board Member, Crohn's and Colitis Foundation of America, Northwest Chapter
- 2009-present Chapter Medical Advisory Committee, Crohn's and Colitis Foundation
- 2012-2018 GI Division Fellowship Selection Committee
- 2014-2015 UW School of Medicine Admissions Committee

15. Research Funding:

Fecal Microbiota Transplantation for Ulcerative Colitis

Role: Principal Investigator

Funding: Broad Foundation

Date: 07/01/2012 – 06/30/2013

Crohn's Allogeneic Transplantation Study (CATS)

Role: Sub-investigator

Funding: Broad Foundation

Date: 05/01/2012 – 10/31/2014

A double-blind, randomized, placebo-controlled, parallel, dose-ranging study to evaluate the efficacy and safety of PF-00547659 in subjects with moderate to severe ulcerative colitis (TURANDOT).

Role: Site principal investigator.

Funding: Pfizer

Date: 04/01/2013 – 04/01/2015

Randomized, double blind, prospective trial investigating the efficacy of Methotrexate in induction and maintenance of steroid free remission in ulcerative colitis (Methotrexate Response In Treatment of UC - MERIT-UC)

Role: Site principal investigator

Sponsor: Clinical Research Alliance—Crohn's and Colitis Foundation of America

Date: 07/01/2013 – 06/30/2014

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endoscopic Remission in Subjects with Moderately to

Severely Active Crohn's Disease who have Inadequately Responded to or are Intolerant to Anti-TNF Therapy (CELEST)
Role: Site Principal Investigator
Sponsor: AbbVie

A Phase 2, Multicenter, Randomized, Parallel-arm, Placebo-Controlled Study of LY3074828 in Subjects with Moderate to Severely Active Crohn's Disease (SERENITY)
Role: Site Principal Investigator
Sponsor: Eli Lilly

A Phase 4 Open-Label Study to Evaluate Vedolizumab IV Dose Optimization on Treatment Outcomes in Nonresponders with Moderately to Severely Active Ulcerative Colitis (ENTERPRET)
Role: Site Principal Investigator
Sponsor: Takeda

A Phase 2b, Double-blind, Randomized, Placebo-controlled, Parallel Group, Dose Ranging Study of Oral PF-06651600 and PF-06700841 as Induction and Chronic Therapy in Subjects with Moderate to Severe Ulcerative Colitis (VIBRATO)
Role: Site Principal Investigator
Sponsor: Pfizer

DIET: Diet as Essential Therapy for Crohn's Disease
Role: Principal Investigator
Funding: Private Donor

16. Bibliography:

(a) Publications in Refereed Journals:

1. Hasan AA, **Zisman T** and Schmaier AH. Identification of cytokeratin 1 as a binding protein and presentation receptor for kininogens on endothelial cells. *Proc Natl Acad Sci U S A*. 1998 Mar 31; 95(7):3615-20. [original work]
2. **Zisman TL** and Kane SV. Current and Future Therapies for Inflammatory Bowel Disease. *Expert Rev Gastroenterol*. 2007; 1(1):89-101. [review]
3. **Zisman TL** and Rubin DT. Prevention of Dysplasia and Cancer in Chronic Inflammatory Bowel Disease: A Role for Chemoprevention. *Practical Gastroenterology*. 2007 Mar; 31(3):43-50. [review]
4. **Zisman TL** and Cohen RD. Pharmacoeconomics and quality of life of current and emerging biologic therapies for inflammatory bowel disease. *Curr Treat Options Gastroenterol*. 2007 Jun; 10(3):185-94. [review]
5. **Zisman TL** and Rubin DT. Cancer and Dysplasia in Inflammatory Bowel Disease, *World J Gastroenterol*. 2008 May; 14(17):2662-9. [review]
6. Nathanson JW, **Zisman T**, Julian C, McCaffrey S and Rubin DT. Identification of Patients at Increased Risk for Colorectal Cancer in an Open Access Endoscopy Center. *J Clin Gastroenterol*. 2008 Oct; 42(9): 1025-31. [original work]
7. **Zisman TL** and Rubin DT. Novel Diagnostic and Prognostic Modalities in Inflammatory Bowel Disease. *Gastroenterol Clin North Am* 2009 Dec;38(4):729-52. [review]
8. **Zisman TL** and Rubin DT. Novel Diagnostic and Prognostic Modalities in Inflammatory Bowel Disease. *Med Clin North Am*. 2010 Jan;94(1):155-78. [review]
9. **Zisman TL**, Bronner MP, Rulyak S, Kowdley KV, Saunders MD, Lee SD, Ko C, Kimmey MB, Stevens A, Maurer J, Brentnall TA. Prospective Study of the Progression of Low-Grade

Dysplasia in Ulcerative Colitis Using Current Cancer Surveillance Guidelines. *Inflamm Bowel Dis*. 2012 Dec;18(12):2240-6. [original work]

10. *Damman CJ, Miller SI, Surawicz CM, **Zisman TL**. The Microbiome and Inflammatory Bowel Disease: Is There a Therapeutic Role for Fecal Microbiota Transplantation? *Am J Gastroenterol* 2012 Oct;107(10):1452-9. [review]
11. *Harper JW, Sinanan MN, **Zisman TL**. Increased body mass index is associated with earlier time to loss of response to infliximab in patients with inflammatory bowel disease. *Inflamm Bowel Dis*. 2013 Sep;19(10):2118-24. [original work]
12. *Damman CJ, Brittnacher MJ, Westerhoff M, Hayden HS, Radey M, Hager KR, Marquis SR, Miller SI, **Zisman TL**. Low Level Engraftment and Improvement Following a Single Colonoscopic Administration of Fecal Microbiota to Patients with Ulcerative Colitis. *PLoS ONE* 2015. Aug 19; 10(8):e0133925. [original work]
13. Vindigni SM, **Zisman TL**, Suskind DL and Damman CJ. The intestinal microbiome, barrier function, and immune system in inflammatory bowel disease: a tripartite pathophysiological circuit with implications for new therapeutic directions. *Ther Adv Gastroenterol* 2016. 9(4):606-25. [review]
14. *Brittnacher MJ, Heltshe SL, Hayden HS, Damman CJ, Hager KR, Radey MC, **Zisman TL**, Suskind DL, Miller SI. GUTSS: An alignment-free sequence comparison method for use in human intestinal microbiome and fecal microbiota transplantation analysis. *PLoS ONE* 2016 Jul 8;11(7):e0158897. [original work]
15. *Harper JW and Zisman TL. The interaction of obesity and inflammatory bowel disease. *World J Gastroenterol* 2016; 22(35): 7868-81. [review]
16. Lane E, **Zisman TL**, Suskind DL. The microbiota in inflammatory bowel disease: current and therapeutic insights. *J Inflamm Res* 2017;10:63-73 [review]
17. Swanson SM, Harper J, **Zisman TL**. Obesity in inflammatory bowel disease: diagnostic and therapeutic implications. *Curr Opin Gastroenterol* 2018 Mar;34(2):112-119. [review]

(b) Book Chapters:

1. **Zisman TL** and Hanauer SB. Ulcerative Colitis and Indeterminate Colitis (book chapter) Practical Gastroenterology and Hepatology—Vol 2. Talley NJ, Kane SV, Wallace M (editors). Wiley-Blackwell Publishing. 2010.
2. **Zisman, TL**. “Inflammatory Bowel Disease.” Just The Facts: Critical Care. Hall, J.B., Schmidt, G.A., Hogarth, D.K (editors) McGraw Hill Publishing. New York 2007.
3. Fausel RA and **Zisman TL**. Medical Therapy for Crohn’s Disease—The Present. Crohn’s Disease: Basic Principles. Krane MK and Fichera A (editors). Springer International Publishing 2015.

(f) Abstracts:

1. Harper JH, Brenner A, **Zisman TL**. Azathioprine versus Methotrexate as Adjuvant Therapy with Infliximab in Biologic Naïve Patients: Equivalent Responses over Three Year Follow-up. *Am J Gastroenterol* 2012 Oct;107(S1): S628.
2. Harper JH and **Zisman TL**. Comparison of Standard Dose Azathioprine versus Low Dose Azathioprine When Used as Adjuvant Therapy with Infliximab in Patients with Inflammatory Bowel Disease. *Am J Gastroenterol* 2012 Oct;107(S1): S628.
3. Hwang C., et al. The Feasibility and Reliability Of Patient-Reported Malnutrition Risk Screening In Inflammatory Bowel Disease. *Gastroenterology* 2018; 154(6):s-796.
4. Panaccione R, Schreiber S, Van Assche G, Reinisch W, Louis E, **Zisman T**, Yacyshyn B, Sedghi S, Goteti S, Lee WJ, Lacerda AP, Ghosh S. Correlation Between Clinical And

Endoscopic Endpoints And Remission Per Inflammatory Bowel Disease Questionnaire Score In Patients With Crohn's Disease: Data From CELEST. UEGW 2018

16. National and International Invitational Lectures:

- Jan 2011 "Minimizing Risk and Maintaining Good Health in IBD", *American College of Gastroenterology Post-Graduate Course*, Las Vegas, NV.
- Jun 2013 "Cancer in IBD and Future Therapies", *Wound Ostomy and Continence Nurses Society national conference*
- May 2014 "Postoperative Medical Management of Crohn's Disease: Prevention and Surveillance Strategies", *American Society of Colon and Rectal Surgeons national conference*